nach oben

Acta Neurologica Belgica

Erschienen in:

21.07.2020 | COVID-19 | Review article Zur Zeit gratis

Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain–Barré syndrome

verfasst von: Giuliana Galassi, Alessandro Marchioni

Erschienen in: Acta Neurologica Belgica | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

In December 2019, a cluster of cases with 2019 Novel Coronavirus pneumonia from Wuhan, China, aroused worldwide concern due to an escalating outbreak in all the countries in the world. Coronavirus belongs to a family of single-stranded RNA viruses, which includes severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV), that have caused human epidemics with high fatality. The spectrum of the novel coronavirus disease (SARS-Co-2 or COVID-19) ranges from asymptomatic infections to fatal pneumonia, and differs from other viral pulmonary infections. MERS-CoV is known to be potentially neuroinvasive. Extensive reports from China documented central and peripheral nervous system involvement in patients with COVID-19, and identified in angiotensin converting enzyme2 (ACE2), which is present in multiple human organs, the functional receptor for this virus. Guillain–Barré syndrome (GBS) has recently been associated to COVID-19 rising concern among physicians. This review summarizes the current state of knowledge on GBS during or after COVID-19 infection, attempting to clarify the pathophysiology of the associated respiratory dysfunction and failure.

Cao Y, Liu X, Xiong L, Cai K (2020) Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. https://doi.org/10.1002/jmv.25822CrossRefPubMedPubMedCentral

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRefPubMed

Guan W-J, Ni Z-Y, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720. https://doi.org/10.1056/NEJMoa2002032CrossRefPubMed

Chen G, Wu D, Guo W et al (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130(5):2620–2629. https://doi.org/10.1172/JCI137244CrossRefPubMedPubMedCentral

Wu C, Chen X, Cai Y et al (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. JAMA Intern Med, China, e200994. https://doi.org/10.1001/jamainternmed.2020.0994CrossRef

Zhang J, Wang X, Jia X et al (2020) Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan China. Clin Microbiol Infect 26(6):767–772. https://doi.org/10.1016/j.cmi.2020.04.012CrossRefPubMedPubMedCentral

Holshue ML, DeBolt C, Lindquist S et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929–936. https://doi.org/10.1056/NEJMoa200119CrossRefPubMedPubMedCentral

Diaz JH (2020) Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 27(3):041. https://doi.org/10.1093/jtm/taaa041CrossRef

Hamming I, Timens W, Bulthuis ML et al (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631–637. https://doi.org/10.1002/path.1570CrossRefPubMedPubMedCentral

10.

Saad M, Omrani AS, Baig K et al (2014) Clinical aspects and outcomes of 70 patients with middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 29:301–306. https://doi.org/10.1016/j.ijid.2014.09.003CrossRefPubMedPubMedCentral

11.

Zhou Y, Han T, Chen J et al (2020) Clinical and autoimmune characteristics of severe and critical cases with COVID-19. Clin Transl Sci. https://doi.org/10.1111/cts.12805CrossRefPubMedPubMedCentral

12.

Wang L, He W, Yu X et al (2020) Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect 80(6):639–645. https://doi.org/10.1016/j.jinf.2020.03.019CrossRefPubMedPubMedCentral

13.

Liu Y, Mao B, Liang S et al (2020) Association between ages and clinical characteristics and outcomes of coronavirus disease 2019. Eur Respir J 55(5):200111. https://doi.org/10.1183/13993003.01112-2020CrossRef

14.

Li Y-C, Bai W-Z, Hashikawa T (2020) The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 92(6):552–555. https://doi.org/10.1002/jmv.25728CrossRefPubMed

15.

Kim JE, Heo JH, Kim HO et al (2017) Neurological complications during treatment of middle east respiratory syndrome. J Clin Neurol 13:227–233. https://doi.org/10.3988/jcn.2017.13.3.227CrossRefPubMedPubMedCentral

16.

Arabi YM, Harthi A, Hussein J et al (2015) Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV). Infection 43:495–501. https://doi.org/10.1007/s15010-015-0720-yCrossRefPubMedPubMedCentral

17.

Wu Y, Xu X, Chen Z et al (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 1591(87):18–22. https://doi.org/10.1016/j.bbi.2020.03.031CrossRef

18.

Yin R, Feng W, Wang T et al (2020) Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019. J Med Virol. https://doi.org/10.1002/jmv.25888CrossRefPubMedPubMedCentral

19.

Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. JAMA Neurol 77(6):1–9. https://doi.org/10.1001/jamaneurol.2020.1127CrossRefPubMedCentral

20.

Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832. https://doi.org/10.1016/j.jns.2020.116832CrossRefPubMedPubMedCentral

21.

Roe K (2020) Explanation for COVID-19 infection neurological damage and reactivations. Transbound Emerg Dis. https://doi.org/10.1111/tbed.13594CrossRefPubMedPubMedCentral

22.

Yashavantha Rao HC, Jayabaskaran C (2020) The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients. J Med Virol 92(7):786–790. https://doi.org/10.1002/jmv.25918CrossRefPubMed

23.

Bertran Recasens B, Martinez-Llorens JM, Rodriguez-Sevilla JJ, Rubio MA (2020) Lack of dyspnea in Covid-19 patients; another neurological conundrum? Eur J Neurol. https://doi.org/10.1111/ene.14265CrossRefPubMedPubMedCentral

24.

Shi H, Han X, Jiang N et al (2020) Radiological findings from 81 patients with covid-19 pneumonia in wuhan, china: a descriptive study. Lancet Infect Dis 20(4):425–434. https://doi.org/10.1016/S1473-3099(20)30086-4CrossRefPubMedPubMedCentral

25.

Hocker S (2017) Primary acute neuromuscular respiratory failure. Neurol Clin 35(04):707–721. https://doi.org/10.1016/j.ncl.2017.06.007CrossRefPubMed

26.

Guidon AC, Amato AA (2020) COVID-19 and neuromuscular disorders. Neurology 94(22):959–969. https://doi.org/10.1212/WNL.0000000000009566CrossRefPubMed

27.

Rajaballyb YA, Goedee HS, Attarian S, Hartung H (2020) Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic. Muscle Nerve. 62(1):34–40. https://doi.org/10.1002/mus.26896CrossRef

28.

Manji H, Carr AS, Brownlee WJ, Lunn MP (2020) Neurology in the time of covid-19. J Neurol Neurosurg Psychiatry 56:570. https://doi.org/10.1136/jnnp-2020-323414CrossRef

29.

Sellner J, Taba P, Oztürk S, Helbok R (2020) The need for neurologists in the care of COVID-19 patients. Eur J Neurol. https://doi.org/10.1111/ene.14257CrossRefPubMedPubMedCentral

30.

International MG/COVID -19 working group, Jacob S, Muppidi S et al (2020) Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci 412:116803. https://doi.org/10.1016/j.jns.2020.116803CrossRefPubMedCentral

31.

ARDS Definition Task force, Ranieri VM, Rubenfeld GD et al (2012) Acute respiratory distress syndrome: the Berlin definition. JAMA 307:2526–2533. https://doi.org/10.1001/jama.2012.5669CrossRef

32.

Gattinoni L, Chiumello D, Caironi P et al (2020) COVID-19 pneumonia different respiratory treatments for different phenotypes. Intensive Care Med 46(6):1099–1102. https://doi.org/10.1007/s00134-020-06033-2CrossRefPubMedPubMedCentral

33.

Gattinoni L, Coppola S, Cressoni M et al (2020) Covid-19 does not lead to a “Typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 201(10):1299–1300. https://doi.org/10.1164/rccm.202003-0817LECrossRefPubMedPubMedCentral

34.

Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A (2020) Coronavirus disease 2019 (COVID-19) a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 14:1–7. https://doi.org/10.2214/AJR.20.23034CrossRef

35.

Gattinoni L, Chiumello D, Rossi S (2020) COVID-19 pneumonia: ARDS or not. Crit Care 24:154. https://doi.org/10.1186/s13054-020-02880-zCrossRefPubMedPubMedCentral

36.

Wakerley BR, Uncini A, Yuki N (2014) Guillain–Barré and miller fisher syndromes – new diagnostic classification. Nat Rev Neurol 10:537–544. https://doi.org/10.1038/nrneurol.2014.138CrossRefPubMed

37.

Wakerley BR, Yuki N (2014) Pharyngeal-cervical-brachial variant of Guillain–Barré syndrome. J Neurol Neurosurg Psychiatry 85:339–344. https://doi.org/10.1136/jnnp-2013-305397CrossRefPubMed

38.

Fokke C, van den Berg B, Drenthen J et al (2014) Diagnosis of Guillain–Barré syndrome and validation of Brighton criteria. Brain 137:33–43. https://doi.org/10.1093/brain/awt285CrossRefPubMed

39.

Hughes RAC, Cornblath DR, Willison HJ (2016) Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain 139:3041–3047. https://doi.org/10.1093/brain/aww247CrossRefPubMed

40.

Leonhard SE, Mandarakas MR, Gondim FAA et al (2019) Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 15:671–683. https://doi.org/10.1038/s41582-019-0250-9CrossRefPubMedPubMedCentral

41.

Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain–Barre’ syndrome. Lancet 388:717–727. https://doi.org/10.1016/S0140-6736(16)00339-1CrossRefPubMed

42.

Doets AY, Verboon C, van den Berg B et al (2018) Regional variation of Guillain–Barré syndrome. Brain 141:2866–2877. https://doi.org/10.1093/brain/awy232CrossRefPubMed

43.

Verboon C, Doets AY, Galassi G et al (2019) Current treatment practice of Guillain–Barré syndrome. Neurology 93:e59–e76. https://doi.org/10.1212/WNL.0000000000007719CrossRefPubMed

44.

Yuki N, Yamada M, Koga M et al (2001) Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49:712–720. https://doi.org/10.1002/ana.1012CrossRefPubMed

45.

Zhang M, Gilbert M, Yuki N et al (2015) Association of anti-GT1a antibodies with an outbreak of Guillain–Barré syndrome and analysis of ganglioside mimicry in an associated campylobacter jejuni strain. PLoS ONE 10:e0131730. https://doi.org/10.1371/journal.pone.0131730CrossRefPubMedPubMedCentral

46.

Hao Y, Wang W, Jacobs BC et al (2019) Antecedent infections in Guillain–Barré syndrome: a single-center, prospective study. Ann Clin Transl Neurol 6:2510–2517. https://doi.org/10.1002/acn3.50946CrossRefPubMedPubMedCentral

47.

Ebrahim Soltani Z, Rahmani F, Rezaei N (2019) Autoimmunity and cytokines in Guillain–Barré syndrome revisited: review of pathomechanisms with an eye on therapeutic options. Eur Cytokine Netw 30(1):1–14. https://doi.org/10.1684/ecn.2019.0424CrossRefPubMed

48.

Islam Z, Papri N, Ara G et al (2019) Risk factors for respiratory failure in Guillain-Barré syndrome in Bangladesh: a prospective study. Ann Clin Transl Neurol 6(2):324–332. https://doi.org/10.1002/acn3.706CrossRefPubMedPubMedCentral

49.

Walgaard C, Lingsma HF, Ruts L et al (2010) Prediction of respiratory insufficiency in Guillain–Barré syndrome. Ann Neurol 67:781–787. https://doi.org/10.1002/ana.21976CrossRefPubMed

50.

Parra B, Lizarazo J, Jiménez-Arango JA et al (2016) Guillain–Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med 375:1513–1523. https://doi.org/10.1056/NEJMoa1605564CrossRefPubMed

51.

Frontera JA, da Silva IR (2016) Zika getting on your nerves? The association with the Guillain–Barré Syndrome. N Engl J Med 375(16):1581–1582. https://doi.org/10.1056/NEJMe1611840CrossRefPubMed

52.

Lucchese G, Kanduc D, Lucchese G et al (2016) Zika virus and autoimmunity: From microcephaly to Guillain–Barré syndrome, and beyond. Autoimmun Rev 15:801–808. https://doi.org/10.1016/j.autrev.2016.03.020CrossRefPubMed

53.

Tsai LK, Hsieh ST, Chao CC et al (2004) Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 61:1669–1673. https://doi.org/10.1001/archneur.61.11.1669CrossRefPubMed

54.

Beydon M, Chevalier K, Al Tabaa O et al (2020) Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217573CrossRefPubMed

55.

Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain–Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 19:383–384. https://doi.org/10.1016/S1474-4422(20)30109-5CrossRefPubMedPubMedCentral

56.

Toscano G, Palmerini F, Ravaglia S et al (2020) Guillain-Barré Syndrome associated with SARS-CoV-2. New Engl J Med. 382(26):2574–2576. https://doi.org/10.1056/NEJMc2009191CrossRefPubMed

57.

Virani A, Rabold E, Hanson T et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2 infection. Idcases 20:e00771. https://doi.org/10.1016/j.idcr.2020.e00771CrossRefPubMedPubMedCentral

58.

Sedaghat Z, Karimi N (2020) Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 76:233–235. https://doi.org/10.1016/j.jocn.2020.04.062CrossRefPubMedPubMedCentral

59.

Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S et al (2020) Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology. https://doi.org/10.1212/WNL.0000000000009619CrossRefPubMed

60.

Dinkin M, Gao V, Kahan J et al (2020) COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. https://doi.org/10.1212/WNL.0000000000009700CrossRefPubMedPubMedCentral

61.

Alberti P, Beretta S, Piatti M et al (2020) Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm 7(4):e741. https://doi.org/10.1212/NXI.0000000000000741CrossRefPubMedPubMedCentral

62.

El Otmani H, El Moutawakil B, Rafai M-A et al (2020) Covid-19 and Guillain-Barré syndrome: more than a coincidence. Rev Neurol (Paris) 176(6):518–519. https://doi.org/10.1016/j.neurol.2020.04.007CrossRef

63.

Coen M, Jeanson G, Alejandro Culebras Almeida L et al (2020) Guillain–Barré syndrome as a complication of SARS-CoV-2 infection. Brain Behav Immun 87:111–112. https://doi.org/10.1016/j.bbi.2020.04.074CrossRefPubMedPubMedCentral

64.

Padroni M, Mastrangelo V, Asioli GM et al (2020) Guillain–Barré syndrome following COVID-19: new infection, old complication? J Neurol 267:1877–1879. https://doi.org/10.1007/s00415-020-09849-6CrossRefPubMedPubMedCentral

65.

Ottaviani D, Boso F, Tranquillini E et al (2020) Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol Sci 41:1351–1354. https://doi.org/10.1007/s10072-020-04449-8CrossRefPubMedPubMedCentral

66.

Juliao Caamaño DS, Alonso BR (2020) Facial diplegia, a possible atypical variant of Guillain-Barré syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci. 77:230–232. https://doi.org/10.1016/j.jocn.2020.05.016CrossRefPubMedPubMedCentral

67.

Chan JL, Ebadi H, Sarna JR (2020) Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection. Can J Neurol Sci 1:10. https://doi.org/10.1017/cjn.2020.106CrossRef

68.

Scheidl E, Canseco Diez D, Hadji-Naumov A, Bereznai J (2020) Guillain-Barré syndrome during SARS-CoV-2 pandemic: a case report and review of recent literature. J Peripher Nerv Syst 25(2):204–207. https://doi.org/10.1111/jns.12382CrossRefPubMed

69.

Vanhorebeek I, Latronico N, Van den Berghe G (2020) ICU-acquired weakness. Intensive Care Med 25(2):204–207. https://doi.org/10.1007/s00134-020-05944-4CrossRef

70.

Magro C, Mulvey JJ, Berlin D et al (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007CrossRefPubMedPubMedCentral

71.

Ferris BG Jr, Warren A, Beals CA (1955) The vital capacity as a measure of the spontaneous breathing ability in poliomyelitis. N Engl J Med 252:618–621. https://doi.org/10.1056/NEJM195504142521504CrossRefPubMed

72.

De Troyer A, Borenstein S, Cordier R (1980) Analysis of lung volume restriction in patients with respiratory muscle weakness. Thorax 35:603–610. https://doi.org/10.1136/thx.35.8.603CrossRefPubMedPubMedCentral

73.

Gibson GJ, Pride NB (1979) Pride NB (1979) Lung mechanic. Am Rev Respir Dis 11:119–120. https://doi.org/10.1164/arrd.1979.119.2P2.119

74.

Chew FT, Ong SY, Hew CL (2003) Severe acute respiratory syndrome coronavirus and viral mimicry. Lancet 361(9374):2081. https://doi.org/10.1016/s0140-6736(03)13652-723CrossRefPubMed

75.

The Lancet Neurology (2020) The Neurological impact of COVID-19. Lancet Neurol 19(6):471. https://doi.org/10.1016/S1474-4422(20)30142-3CrossRefPubMedPubMedCentral

76.

Dalakas MC (2020) Guillain-Barre’ syndrome: the first documented CoVID-19-triggered autoimmune neurologic disease. Neurol Neuroimmunol Neuroinflamm 7:e781. https://doi.org/10.1212/NXI.0000000000000781CrossRefPubMedPubMedCentral

Titel: Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain–Barré syndrome
verfasst von: Giuliana Galassi
Alessandro Marchioni
Publikationsdatum: 21.07.2020
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Acta Neurologica Belgica / Ausgabe 5/2020
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-020-01421-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Clinical characteristic of 15 cases of cryptococcal meningitis treated with Ommaya reservoir

Association of dynamic and widespread mechanical sensitivity in cluster headache

Neurological manifestations of COVID-19, SARS and MERS

Cyclic vomiting syndrome associated with benign paroxysmal vertigo: a case report

Angiographically occult cerebral vascular malformation mimicking cortical venous sinus thrombosis: case report